The FDA has initiated a review of telehealth marketing strategies employed for GLP-1 drugs, which have seen a rise in popularity among healthcare providers.
This regulatory focus may lead to changes in how these medications are marketed and prescribed, potentially affecting the operational frameworks of telehealth companies.
As the landscape evolves, stakeholders must assess the implications for capacity and throughput in telehealth services related to GLP-1 drug prescriptions.